Top

Published in:

Open Access 05-01-2024 | Multiple Sclerosis | REVIEW

Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review

Authors: Sharon Stoll, Kathleen Costello, Scott D. Newsome, Hollie Schmidt, Amy B. Sullivan, Barry Hendin

Published in: Neurology and Therapy | Issue 1/2024

Abstract

Shared decision-making (SDM) between the patient and their healthcare provider (HCP) in developing treatment plans is increasingly recognized as central to improving treatment adherence and, ultimately, patient outcomes. In multiple sclerosis (MS), SDM is particularly crucial for optimizing treatment in a landscape that has grown more complex with the availability of newer, high-efficacy MS therapies. However, little direct evidence on the effectiveness of SDM is available to guide practice. Multiple factors, including patient age, ethnic background, perceptions, invisible MS symptoms, and psychological comorbidities can influence a patient’s willingness and ability to participate in SDM. HCPs need to appreciate these factors and ask the right questions to break down obstacles to SDM. The HCP has a responsibility to help patients feel adequately informed and comfortable in having an active role in their care. This review identifies potential barriers to SDM and provides a strategy for HCPs to overcome these obstacles through patient (and caregiver) discussions to ensure optimal patient satisfaction with treatment and thus the best possible outcomes for their patients.

World Medical Association. WMA Declaration of Geneva. https://www.wma.net/policies-post/wma-declaration-of-geneva/. Accessed 16 Sep 2022.

Colligan E, Metzler A, Tiryaki E. Shared decision-making in multiple sclerosis. Mult Scler. 2017;23:185–90.PubMedCrossRef

Filippi M, Danesi R, Derfuss T, et al. Early and unrestricted access to high-efficacy disease-modifying therapies: a consensus to optimize benefits for people living with multiple sclerosis. J Neurol. 2022;269:1670–7.PubMedCrossRef

Samjoo IA, Worthington E, Drudge C, et al. Efficacy classification of modern therapies in multiple sclerosis. J Comp Eff Res. 2021;10:495–507.PubMedCrossRef

Scolding N, Barnes D, Cader S, et al. Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis. Pract Neurol. 2015;15:273–9.PubMedCrossRef

Tintore M, Alexander M, Costello K, et al. The state of multiple sclerosis: current insight into the patient/health care provider relationship, treatment challenges, and satisfaction. Patient Prefer Adherence. 2017;11:33–45.PubMedCrossRef

Ben-Zacharia A, Adamson M, Boyd A, et al. Impact of shared decision making on disease-modifying drug adherence in multiple sclerosis. Int J MS Care. 2018;20:287–97.PubMedPubMedCentralCrossRef

Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90:777–88.PubMedCrossRef

Yeandle D, Rieckmann P, Giovannoni G, Alexandri N, Langdon D. Patient power revolution in multiple sclerosis: navigating the new frontier. Neurol Ther. 2018;7:179–87.PubMedPubMedCentralCrossRef

10.

Cofield SS, Thomas N, Tyry T, Fox RJ, Salter A. Shared decision making and autonomy among US participants with multiple sclerosis in the NARCOMS Registry. Int J MS Care. 2017;19:303–12.PubMedPubMedCentralCrossRef

11.

Alonso RN, Chertcoff A, Eizaguirre MB, et al. Decision making process in multiple sclerosis: an Argentine pilot study. Mult Scler Relat Disord. 2022;61:103751.PubMedCrossRef

12.

Comi G, Radaelli M, Soelberg SP. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389:1347–56.PubMedCrossRef

13.

Simonsen CS, Flemmen HO, Broch L, et al. Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry. Front Neurol. 2021;12:693017.PubMedPubMedCentralCrossRef

14.

He A, Merkel B, Brown JWL, et al. Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol. 2020;19:307–16.PubMedCrossRef

15.

Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536–41.PubMedPubMedCentralCrossRef

16.

Merkel B, Butzkueven H, Traboulsee AL, Havrdova E, Kalincik T. Timing of high-efficacy therapy in relapsing-remitting multiple sclerosis: a systematic review. Autoimmun Rev. 2017;16:658–65.PubMedCrossRef

17.

Biogen Inc. TYSABRI prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125104s973s975lbl.pdf. Accessed 12 Oct 2022.

18.

Merck. MAVENCLAD prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022561s006lbl.pdf. Accessed 12 Oct 2022.

19.

Genentech Inc. OCREVUS prescribing information. https://www.gene.com/download/pdf/ocrevus_prescribing.pdf. Accessed 12 Oct 2022.

20.

Manzano A, Eskyte I, Ford HL, et al. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;46:102507.PubMedCrossRef

21.

Coyle PK. Management of women with multiple sclerosis through pregnancy and after childbirth. Ther Adv Neurol Disord. 2016;9:198–210.PubMedPubMedCentralCrossRef

22.

Villaverde-Gonzalez R. Updated perspectives on the challenges of managing multiple sclerosis during pregnancy. Degener Neurol Neuromuscul Dis. 2022;12:1–21.PubMedPubMedCentral

23.

Kew KM, Malik P, Aniruddhan K, Normansell R. Shared decision-making for people with asthma. Cochrane Database Syst Rev. 2017;10:CD012330.

24.

Peterson EB, Ostroff JS, DuHamel KN, et al. Impact of provider-patient communication on cancer screening adherence: a systematic review. Prev Med. 2016;93:96–105.PubMedPubMedCentralCrossRef

25.

Saheb Kashaf M, McGill ET, Berger ZD. Shared decision-making and outcomes in type 2 diabetes: a systematic review and meta-analysis. Patient Educ Couns. 2017;100:2159–71.PubMedCrossRef

26.

Tan ASL, Mazor KM, McDonald D, et al. Designing shared decision-making interventions for dissemination and sustainment: can implementation science help translate shared decision making into routine practice? MDM Policy Pract. 2018;3:2381468318808503.PubMedPubMedCentral

27.

Elwyn G, Frosch DL, Kobrin S. Implementing shared decision-making: consider all the consequences. Implement Sci. 2016;11:114.PubMedPubMedCentralCrossRef

28.

Consortium of Multiple Sclerosis Centers. NARCOMMS Registry for multiple sclerosis. https://www.narcoms.org/. Accessed 28 Oct 2022.

29.

COViMS. COVID-19 Infections in MS and Related Diseases. https://www.covims.org/. Accessed 22 Nov 2022.

30.

Briggs FBS, Mateen FJ, Schmidt H, et al. COVID-19 vaccination reactogenicity in persons with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022;9:e1104.PubMedCrossRef

31.

Vogel AC, Schmidt H, Loud S, McBurney R, Mateen FJ. Impact of the COVID-19 pandemic on the health care of >1,000 people living with multiple sclerosis: a cross-sectional study. Mult Scler Relat Disord. 2020;46:102512.PubMedPubMedCentralCrossRef

32.

NAAMS Registry. National African Americans with MS Registry. https://www.naamsr.org/. Accessed 22 Nov 2022.

33.

Amezcua L, Oksenberg JR, McCauley JL. MS in self-identified Hispanic/Latino individuals living in the US. Mult Scler J Exp Transl Clin. 2017;3:2055217317725103.PubMedPubMedCentral

34.

Shinkunas LA, Klipowicz CJ, Carlisle EM. Shared decision making in surgery: a scoping review of patient and surgeon preferences. BMC Med Inform Decis Mak. 2020;20:190.PubMedPubMedCentralCrossRef

35.

Morrison T, Foster E, Dougherty J, Barton J. Shared decision making in rheumatology: a scoping review. Semin Arthritis Rheum. 2022;56:152041.PubMedCrossRef

36.

Wyatt KD, Branda ME, Inselman JW, et al. Genders of patients and clinicians and their effect on shared decision making: a participant-level meta-analysis. BMC Med Inform Decis Mak. 2014;14:81.PubMedPubMedCentralCrossRef

37.

Adisso EL, Zomahoun HTV, Gogovor A, Legare F. Sex and gender considerations in implementation interventions to promote shared decision making: a secondary analysis of a Cochrane systematic review. PLoS ONE. 2020;15:e0240371.PubMedPubMedCentralCrossRef

38.

Mead EL, Doorenbos AZ, Javid SH, et al. Shared decision-making for cancer care among racial and ethnic minorities: a systematic review. Am J Public Health. 2013;103:e15-29.PubMedPubMedCentralCrossRef

39.

Hughes TM, Merath K, Chen Q, et al. Association of shared decision-making on patient-reported health outcomes and healthcare utilization. Am J Surg. 2018;216:7–12.PubMedCrossRef

40.

Barton JL, Trupin L, Tonner C, et al. English language proficiency, health literacy, and trust in physician are associated with shared decision making in rheumatoid arthritis. J Rheumatol. 2014;41:1290–7.PubMedPubMedCentralCrossRef

41.

Berrios-Rivera JP, Street RL Jr, Garcia Popa-Lisseanu MG, et al. Trust in physicians and elements of the medical interaction in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum. 2006;55:385–93.PubMedCrossRef

42.

Ward MM, Sundaramurthy S, Lotstein D, Bush TM, Neuwelt CM, Street RL Jr. Participatory patient-physician communication and morbidity in patients with systemic lupus erythematosus. Arthritis Rheum. 2003;49:810–8.PubMedCrossRef

43.

Alonso R, Carnero Contentti E, Grana M, et al. Shared decision making in the treatment of multiple sclerosis: a consensus based on Delphi methodology. Mult Scler Relat Disord. 2022;70:104465.PubMedCrossRef

44.

Pietrolongo E, Giordano A, Kleinefeld M, et al. Decision-making in multiple sclerosis consultations in Italy: third observer and patient assessments. PLoS ONE. 2013;8:e60721.PubMedPubMedCentralCrossRef

45.

Ben-Zacharia AB, Lee JM, Kahle JS, Lord B. Shared decision-making in multiple sclerosis physical symptomatic care: a systematic review. Ther Adv Chronic Dis. 2023;14:20406223231172920.PubMedPubMedCentralCrossRef

46.

Held Bradford E, Finlayson M, White Gorman A, Wagner J. Maximizing gait and balance: behaviors and decision-making processes of persons with multiple sclerosis and physical therapists. Disabil Rehabil. 2018;40:1014–25.PubMedCrossRef

47.

Saposnik G, Sempere AP, Prefasi D, et al. Decision-making in multiple sclerosis: the role of aversion to ambiguity for therapeutic inertia among neurologists (DIScUTIR MS). Front Neurol. 2017;8:65.PubMedPubMedCentralCrossRef

48.

Kremer IEH, Evers S, Jongen PJ, Hiligsmann M. Comparison of preferences of healthcare professionals and MS patients for attributes of disease-modifying drugs: a best-worst scaling. Health Expect. 2018;21:171–80.PubMedCrossRef

49.

Members of the MS in the 21st Century Steering Group, Rieckmann P, Centonze D, et al. Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: a combined perspective from the MS in the 21st Century Steering Group. Mult Scler Relat Disord. 2018;19:153–160.

50.

Heesen C, Haase R, Melzig S, et al. Perceptions on the value of bodily functions in multiple sclerosis. Acta Neurol Scand. 2018;137:356–62.PubMedCrossRef

51.

Visser LA, Louapre C, Uyl-de Groot CA, Redekop WK. Patient needs and preferences in relapsing-remitting multiple sclerosis: a systematic review. Mult Scler Relat Disord. 2020;39:101929.PubMedCrossRef

52.

Kumar J, Cambron-Mellott MJ, Tencer T, Will O, Mackie DS, Beusterien K. Patient and neurologist preferences in the United States for relapsing-remitting multiple sclerosis treatments: findings from a discrete choice experiment. Patient Prefer Adherence. 2021;15:1515–27.PubMedPubMedCentralCrossRef

53.

Reen GK, Silber E, Langdon DW. Multiple sclerosis patients’ understanding and preferences for risks and benefits of disease-modifying drugs: a systematic review. J Neurol Sci. 2017;375:107–22.PubMedCrossRef

54.

Schlegel V, Leray E. From medical prescription to patient compliance: a qualitative insight into the neurologist-patient relationship in multiple sclerosis. Int J MS Care. 2018;20:279–86.PubMedPubMedCentralCrossRef

55.

Duffy LV, Sarill K, Forbes P, Camposano S, McCabe M. Shared decision making and disease modifying therapy in families of children and adolescents with pediatric onset multiple sclerosis. J Pediatr Nurs. 2021;61:404–9.PubMedCrossRef

56.

Wattjes MP, Rovira A, Miller D, et al. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. Nat Rev Neurol. 2015;11:597–606.PubMedCrossRef

57.

Engels K, Schiffmann I, Weierstall R, et al. Emotions towards magnetic resonance imaging in people with multiple sclerosis. Acta Neurol Scand. 2019;139:497–504.PubMedCrossRef

58.

Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287–300.PubMedCrossRef

59.

Saposnik G, Andhavarapu S, Fernandez O, et al. Factors associated with treatment escalation among MS specialists and general neurologists: results from an international cojoint study. Mult Scler Relat Disord. 2022;58:103404.PubMedCrossRef

60.

Freund M, Schiffmann I, Rahn AC, et al. Understanding Magnetic Resonance Imaging in Multiple Sclerosis (UMIMS): development and piloting of an online education program about magnetic resonance imaging for people with multiple sclerosis. Front Neurol. 2022;13:856240.PubMedPubMedCentralCrossRef

61.

Cadden MH, Arnett PA, Tyry TM, Cook JE. Judgment hurts: the psychological consequences of experiencing stigma in multiple sclerosis. Soc Sci Med. 2018;208:158–64.PubMedCrossRef

62.

Hanna M, Strober LB. Anxiety and depression in multiple sclerosis (MS): antecedents, consequences, and differential impact on well-being and quality of life. Mult Scler Relat Disord. 2020;44:102261.PubMedPubMedCentralCrossRef

63.

Goodworth MC, Stepleman L, Hibbard J, et al. Variables associated with patient activation in persons with multiple sclerosis. J Health Psychol. 2016;21:82–92.PubMedCrossRef

64.

Possa MF, Minacapelli E, Canale S, Comi G, Martinelli V, Falautano M. The first year after diagnosis: psychological impact on people with multiple sclerosis. Psychol Health Med. 2017;22:1063–71.PubMedCrossRef

65.

Wang G, Marrie RA, Salter AR, et al. Health insurance affects the use of disease-modifying therapy in multiple sclerosis. Neurology. 2016;87:365–74.PubMedPubMedCentralCrossRef

66.

Frost N, Freeman J, Brixner D, Mort J, Clem J, Ngorsuraches S. Patients’ preferences and willingness-to-pay for disease-modifying therapies. Mult Scler Relat Disord. 2019;35:55–60.PubMedCrossRef

67.

Poudel N, Banjara B, Kamau S, Frost N, Ngorsuraches S. Factors influencing patients’ willingness-to-pay for disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2021;48:102720.PubMedCrossRef

68.

Mayo CD, Farzam-Kia N, Ghahari S. Identifying barriers to and facilitators of health service access encountered by individuals with multiple sclerosis. Int J MS Care. 2021;23:37–44.PubMedPubMedCentralCrossRef

69.

Kuusisto H, Apila S, Saranto K. Information provision and quality. A pilot study on shared decision-making in multiple sclerosis. Stud Health Technol Inform. 2022;295:179–82.PubMed

70.

De Kleermaeker F, Uitdehaag BMJ, van Oosten BW. Patients’ expectations of autologous hematopoietic stem cell transplantation as a treatment for MS. Mult Scler Relat Disord. 2020;37:101467.PubMedCrossRef

71.

Wicks CR, Sloan R, DiMauro S, et al. Patients’ experiences of self-identification, seeking support, and anticipation of potential relapse in multiple sclerosis. Mult Scler Relat Disord. 2021;56:103259.PubMedCrossRef

72.

Kesselring J, Boyko A, Laroni A, Bharadia T, van Galen P, Alexandri N. Caregiver involvement in MS: duty or disruption? Neurol Ther. 2022;11:9–20.PubMedCrossRef

73.

Reen GK, Silber E, Langdon DW. Best methods of communicating clinical trial data to improve understanding of treatments for patients with multiple sclerosis. Value Health. 2018;21:762–6.PubMedCrossRef

74.

Hoffmann JA, Bareuther L, Schmidt R, Dettmers C. The relation between memory and decision-making in multiple sclerosis patients. Mult Scler Relat Disord. 2020;37:101433.PubMedCrossRef

75.

Bruce JM, Jarmolowicz DP, Lynch S, et al. How patients with multiple sclerosis weigh treatment risks and benefits. Health Psychol. 2018;37:680–90.PubMedCrossRef

76.

Schiffmann I, Freund M, Vettorazzi E, et al. Assessing the effect of an evidence-based patient online educational tool for people with multiple sclerosis called UMIMS—understanding magnetic resonance imaging in multiple sclerosis: study protocol for a double-blind, randomized controlled trial. Trials. 2020;21:1008.PubMedPubMedCentralCrossRef

77.

Heesen C, Rahn AC. Guest Editorial: shared decision making in managing multiple sclerosis: revisiting the research agenda. Int J MS Care. 2018;20:v–vi.PubMedPubMedCentralCrossRef

78.

Cocco E, Caoci A, Lorefice L, Marrosu MG. Perception of risk and shared decision making process in multiple sclerosis. Expert Rev Neurother. 2017;17:173–80.PubMedCrossRef

79.

Rosenbaum L. The paternalism preference—choosing unshared decision making. N Engl J Med. 2015;373:589–92.PubMedCrossRef

80.

Köpke S, Solari A, Khan F, Heesen C, Giordano A. Information provision for people with multiple sclerosis. Cochrane Database Syst Rev. 2014:CD008757.

81.

Schneider A, Fasshauer E, Scheiderbauer J, et al. Development and evaluation of evidence-based patient information handbooks about multiple sclerosis immunotherapies. Mult Scler Relat Disord. 2022;60:103728.PubMedCrossRef

82.

Bansback N, Chiu JA, Metcalfe R, et al. Preliminary testing of a patient decision aid for patients with relapsing-remitting multiple sclerosis. Mult Scler J Exp Transl Clin. 2021;7:20552173211029970.PubMedPubMedCentral

83.

Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2017;4:CD001431.PubMed

84.

Stacey D, Legare F, Lewis KB. Patient decision aids to engage adults in treatment or screening decisions. JAMA. 2017;318:657–8.PubMedCrossRef

85.

Col N, Alvarez E, Springmann V, et al. A novel tool to improve shared decision making and adherence in multiple sclerosis: development and preliminary testing. MDM Policy Pract. 2019;4:2381468319879134.PubMedPubMedCentral

Title: Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review
Authors: Sharon Stoll
Kathleen Costello
Scott D. Newsome
Hollie Schmidt
Amy B. Sullivan
Barry Hendin
Publication date: 05-01-2024
Publisher: Springer Healthcare
Keywords: Multiple Sclerosis
MS-Therapeutics
Published in: Neurology and Therapy / Issue 1/2024
Print ISSN: 2193-8253
Electronic ISSN: 2193-6536
DOI: https://doi.org/10.1007/s40120-023-00573-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2024

Impact of Migraine on Daily Life: Results of the Observational survey of the Epidemiology, Treatment, and Care of Migraine (OVERCOME [Japan]) Study

Evaluating Elements of the Care Partner Experience in Individuals Who Care for People with Alzheimer's Disease Across the Severity Spectrum

Bioequivalence Study of Two Tablet Formulations of Clonazepam 2 mg: A Randomized, Open-Label, Crossover Study in Healthy Mexican Volunteers Under Fasting Conditions

Recognition and Practice of Hypopituitarism After Traumatic Brain Injury and Subarachnoid Hemorrhage in Japan: A Survey

Correction: Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis

Comparing the Efficacy and Safety of Galcanezumab Versus Rimegepant for Prevention of Episodic Migraine: Results from a Randomized, Controlled Clinical Trial